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           Brugada syndrome is a unique form of idiopathic ventricular fibrillation (VF), and is
characterized by an ECG pattern with right bundle branch block (J wave),   ST-segment
elevation and terminal T-wave inversion in leads V1 through V3 1,2,3,4,5,6,7,8,9,10.  It accounts
for approximately 20% of all cases of sudden cardiac death in patients with structurally normal
hearts and appears to be more frequent in Southeast Asia than in other regions5.  To date, the
only established therapy for preventing sudden cardiac death due to VF in this disease is an
implantation of an implantable cardioverter defibrillator (ICD)1,2,3,4.   Although there is no
room for discussion regarding the excellent and uniform efficacy of ICDs for terminating VF,
the effect is confined to the termination of VF, and ICDs cannot contribute to the prevention of
VF.  Therefore, there are some concerns regarding ICD therapy.  The first is electrical storm
associated with VF or polymorphic ventricular tachycardia, which is defined as frequent
appropriate ICD shock deliveries for ventricular tachyarrhythmias of >3 times over 24 hours. 
Chalvidan et al. 10, reported a patient who suffered from incessant VF episodes (electrical
storm) and became near-fatal, but subsequently fully recovered.  The second is ICD related
complications including lead dislodgment, inappropriate shock delivery, infection requiring
ICD removal and so on 11,12,13.  The third is the indication of ICDs for infant cases of Brugada
syndrome, in which the size of the ICD is too large for implantation 11,12,13.  A new therapy
other than ICD implantation to overcome these concerns seems to be urgent.
Cellular mechanism
               Brugada syndrome is suggested to be a primary electrical disease, and two dozen
mutations of the cardiac sodium channel gene “SCN5A”, which lead to a loss of the channel
function, have been found in about 15-20 % of patients with Brugada syndrome, and an
autosomal mode of transmission has been demonstrated 4,5,6,7,8. 
            The ionic and cellular basis for the ST-segment elevation in Brugada syndrome is
hypothesized to be due to an outward shift in the balance of the membrane ionic currents at the
end of phase 1 and phase 2 of the action potential, in which an outward current is mainly due to
the activation of the transient outward current (Ito), and the inward current is mainly due to the
activation of an inward calcium current (ICa)￿and an inactivating component of an inward
sodium current (INa).  The net outward shift of this current balance leads to a loss of the dome
or phase 2 of the action potential.  Such changes may affect the right ventricular epicardium
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more markedly than the endocardium and produce a marked voltage gradient in the membrane
potential between the end- and epi-cardial sides of the right ventricular muscle fibers during the
phase 2 (a change corresponding to the characteristic ST-segment elevation in V1 through V3
in the ECGs of Brugada Syndrome4,6,7,8.  
            The loss of the action potential dome in the epicardium but not in the endocardium
results   in   the   development   of   a   marked   transmural   dispersion   of   repolarization   and
refractoriness, responsible for the development of a vulnerable window during which a
premature impulse or extrasystole can induce a reentrant arrhythmia.  Because the loss of the
action potential dome in the epicardium is usually heterogeneous, it leads to the development of
epicardial dispersion of repolarization and refractoriness.  Conduction of the action potential
dome from sites at which it is maintained to sites at which it is lost causes local re-excitation
via a phase 2 reentry mechanism, leading to the development of a very closely coupled
extrasystole, which captures the vulnerable window across the wall, thus triggering a circus
movement reentry in the form of VT or VF 4,6,7,8. 
            In patients with Brugada syndrome, an abnormal spike-and-dome configuration of the
epicardial monophasic action potentials (MAPs) obtained from the right ventricular outflow
tract, may create a prominent J point elevation14.  Furthermore, a MAP and repolarization of
longer duration in the epicardium than in the endocardium, resulting from a delayed dome
formation, suggests a reversal current flow during phase 3 of the action potential.  The longer
duration of the action potential in the epicardium may have created the typical terminal T-wave
inversion observed in Brugada syndrome 14.   Antelevitch et al.,  4,7,8  suggested that the
arrhythmogenic substrate arises when a further shift in the balance of the current leads to a loss
of the action potential dome at some epicardial sites but not others.  Actually, Nagase et al.15,
reported that a delayed potential was observed in the epicardial electrogram of the right
ventricular outflow tract but not others, which was considered to be the second upstroke of the
epicardial action potential (epicardial echo beat) generated by local and concealed phase 2
reentry 16.  
Pharmacological therapy based on the cellular mechanism
            A variety of pathophysiologic conditions and pharmacologic interventions, which either
increase the membrane outward currents or reduce the inward currents should produce a loss of
the action potential dome in the right ventricular epicardium and facilitate the occurrence of
VF.  Phase 2 of the action potential could be abolished by reducing the INa as predicted by the
ST-segment elevation after the application of Class IC agents and restored by increasing the
inward current, e.g., by enhancing the ICa or by decreasing the outward Ito current, e.g., by the
application of quinidine as reported 4,7,8. 
            There are many pharmacologic therapies that have been clinically examined. Class IC
agents are clearly contraindicated because theses drugs reduce the INa as mentioned above 17.
Class IA agents, including procainamide and disopyramide, are contraindicated since these
drugs strongly depress the INa but only mildly affect Ito, and are well known to exacerbate the
ST elevation and occurrence of VF4,7,8,9.  Class IB agents, which lack an Ito blocking effect and
display little use-dependence owing to a rapid dissociation from the sodium channel, are not at
all effective in the normalization of the ST-segment elevation 13.  Both amiodarone and beta-
blockers are also shown to be ineffective4,7,8,9. 
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            Because the presence of a prominent Ito is at the heart of the mechanism underlying
Brugada syndrome, any agent that blocks this current in the heart is likely to be protective
4,6,7,8.  At the time of writing this review, there was no drug developed that could cardio-
selectively block the Ito.  An isolated case report showed that DDD-pacing at a relatively high
rate is effective in decreasing the Ito   (and hence suppressing VF), possibly because the
repriming time of the Ito channels is reported to be fairly long 18.   There is, however, no
systematic study to examine the effect of relatively high rate pacing on the prevention of VF. 
Quinidine, another class IA agent, has been shown to directly inhibit Ito in addition to a
secondary inhibition due to an increase in the heart rate by a vagolytic action4,7,8.  Experimental
studies have shown quinidine to be effective in restoring the epicardial action potential dome,
thus normalizing the ST-segment and preventing phase 2 reentry and polymorphic VT in
experimental models of Brugada syndrome 7,8.  
            Belhassen et al. 11, reported very important and provocative observations regarding the
effect of quinidine on the prevention of VF in 34 consecutive patents with idiopathic VF, 5 of
whom met the diagnostic criterion of Brugada syndrome.  In the study, electrophysiologic study
(EP)-guided therapy with class IA agents (mainly quinidine) was performed.   These agents
effectively prevented the induction of sustained polymorphic ventricular tachycardia (SPVT)
and/or VF in 26 of 27 patients (96%), in all of whom SPVT or VF was induced in the baseline
EP studies.   Of the 23 patients treated with these medications, no patients died or had a
sustained ventricular arrhythmia during a mean follow-up period of 9.1+5.6 years. They
concluded that EP-guided therapy with class IA agents (mainly quinidine) was a reasonable,
safe and effective approach for the long-term management of patients with idiopathic VF
including Brugada syndrome.   Although there have been no randomized placebo-controlled
prospective studies of EP-guided quinidine therapy, I think that quinidine is a promising
antiarrhythmic agent.   The experimental antiarrhythmic agent, tedisamil, with its potent Ito,
among other outward current, blocking action, has been suggested as a therapeutic candidate8.
This drug may be more potent than quinidine because it lacks the relatively strong inward
current blocking actions of quinidine. 
            There are, however, some limitations in using quinidine for the prevention of VF in
patients with Brugada syndrome.  There are some risks with antiarrhythmic agents with regard
to the potential for a loss of efficacy or proarrhythmic effects under a number of conditions
including hypokalemia, hypomagnesemia, bradycardia, therapy with other agents that alter
repolarization, metabolic inhibitors, and changes in myocardial substrates.   Furthermore,
quinidine is known to have other non-cardiac side effects including abdominal cramping,
diarrhea, cinchonism, which consists of decreased hearing, tinnitus, and blurred vision,
thrombocytopenia, lupus syndrome, and anticholinergic side effects including a dry mouth,
urinary retention and so on.    These side effects may affect the compliance with the drug 11.
The anticholinergic action on the heart might contribute to the anti-VF effect of the drug by
increasing the heart rate 13. 
            Another approach for the prevention of VF in patients with Brugada syndrome is to
increase the ICa by promoting an intracellular level of cyclic-AMP.  Intravenous Isoproterenol
administration is especially known to be effective in suppressing ST elevation in leads V1
through V3 in Brugada syndrome patients, and to restore the action potential dome in models of
this syndrome 4,7,8 and patients with Brugada syndrome 9,19, because it markedly increases the
ICa secondary to an elevation in the intracellular level of cyclic-AMP. 
            Cilostazol, a new oral phosphodiesterase type-III inhibitor is primarily used as a strong
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antiplatelet agent, but has been shown to increase the ICa and modestly increase the heart rate as
well as contractile function. All these effects are secondary to an increased level of the cyclic-
AMP caused by an inhibition of phosphodiesterase type-III activity, in guinea-pig ventricular
myocytes and papillary muscles 20.  From these findings, it is reasonable to expect that this
drug has an antiarrhythmic efficacy for preventing the VF often observed in patients with
Brugada syndrome, because it increases the ICa  due to inhibition of the phosphodiesterase
activity in the ventricular myocytes and decreases the Ito due to an increased heart rate which
again is secondary to an increased ICa in the sinus node.  I recently presented a case of a 67-
year-old man with Brugada syndrome, in whom daily episodes of ventricular fibrillation
occurred early in the morning for 4 days straight and the VF was completely prevented by an
oral administration of cilostazol 21.  This effect was confirmed by the on-and-off challenge test,
in which the discontinuation of this drug resulted in recurrence of VF, and the resumption of
this drug again prevented the VF.  This effect may be related to the suppression of the Ito
secondary to an increase in the heart rate and/or increase in the Ica due to an elevation in the
intracellular   cyclic-AMP   concentration   via   inhibition   of   phosphodiesterase   activity.   I
performed a long-term follow-up with cilostazol in three patients (the follow-up periods were
12, 26 and 32 months, respectively), and in all an ICD was implanted for the termination of
spontaneous VF.  In all the patients several VF episodes were observed over a one year period
prior to the cilostazol, no VF was recorded by the ICD memory and the patients were free from
symptoms under 100-200 mg/day of cilostazol.   Further study is needed to examine the
effectiveness of the drug.
Practical way to use anti-VF drugs
            In patients who undergo aborted sudden cardiac death or syncope of unknown origin
(symptomatic Brugada syndrome), no one argues that the implantation of an ICD is the first-
line therapy regardless of the findings of the EP study.  For those patients, drug therapy plays
not a contradictory but a complimentary role to the ICD by reducing the number of ICD shock
deliveries.   Prevention of VF contributes to the improvement in the quality of life of the
patients by avoiding uncomfortable ICD shock deliveries.
            As mentioned above, Belhassen et al. 11, performed EP-guided medical therapy in 34
patients with idiopathic VF, in 5 of whom the criterion of Brugada syndrome were fulfilled, and
reported excellent long-term results. Although medical therapy requires markers that can
accurately predict the preventive effect of VF over a long-term period, there, however, seems to
be no reliable marker.   An EP study is usually used to examine the preventive effects of
antiarrhythmic agents on sustained ventricular tachycardia in patients with structural heart
disease, whereas the prognostic value of the EP study in predicting life-threatening events in
Brugada   syndrome   is   still   controversial.   Brugada   et   al.,  3  suggested   that   among   the
asymptomatic patients, the inducibility of VT during the EP study might be a prognostic marker
of risk.  Studies by Priori et al., 22 and Kanda et al., 23 failed to find an association between the
inducibility and recurrence of VT/VF in patients with Brugada syndrome regardless of whether
it was symptomatic or asymptomatic.  As Belhassen suggested 13, the difference might be due
to the VF induction protocol in the EP study, in which Belhassen et al., used a stimulus current
intensity of five times the diastolic threshold along with the use of repetition of double and
triple extrastimulation at the shortest coupling intervals that resulted in ventricular capture. 
Further appropriate clinical trials are needed to clarify this issue.
               In   patients   with   asymptomatic Brugada syndrome who are family members of
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symptomatic Brugada syndrome patients, the same strategy as that for the symptomatic
Brugada syndrome patients should be considered 2,3,4.  In another asymptomatic-patient group
in whom an ECG that discloses the Brugada sign is performed for routine reasons such as a
workup prior to surgery or sport license or screening for insurance, risk stratification to find the
patients   at   high   risk   is   needed   because   in   most   cases   these   patients   have   a   benign
prognosis3,22,23.  Antzelevitch et al. 4, recommended that all asymptomatic patients with the
Brugada sign should undergo an EP study for risk stratification, and, if inducible, an ICD
should be implanted since Brugada et al.3, reported that an overall 8% life-threatening event
rate was found in initially asymptomatic patients.  Belhassen et al.,13 suggested that EP study-
guided quinidine therapy might become an alternative to ICD therapy for prophylaxis of
arrhythmic events in these patients. Further appropriate clinical trials are needed.
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